

Michelle A Elliott

List of Publications by Citations

Source: <https://exaly.com/author-pdf/5921005/michelle-a-elliott-publications-by-citations.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

122
papers

1,806
citations

22
h-index

41
g-index

124
ext. papers

2,108
ext. citations

3.7
avg. IF

4.58
L-index

#	Paper	IF	Citations
122	A phase 2 trial of combination low-dose thalidomide and prednisone for the treatment of myelofibrosis with myeloid metaplasia. <i>Blood</i> , 2003 , 101, 2534-41	2.2	255
121	Splenic irradiation for symptomatic splenomegaly associated with myelofibrosis with myeloid metaplasia. <i>British Journal of Haematology</i> , 1998 , 103, 505-11	4.5	115
120	Posttransplantation thrombotic thrombocytopenic purpura: a single-center experience and a contemporary review. <i>Mayo Clinic Proceedings</i> , 2003 , 78, 421-30	6.4	102
119	Thalidomide treatment in myelofibrosis with myeloid metaplasia. <i>British Journal of Haematology</i> , 2002 , 117, 288-96	4.5	97
118	Thalidomide in myelofibrosis with myeloid metaplasia: a pooled-analysis of individual patient data from five studies. <i>Leukemia and Lymphoma</i> , 2002 , 43, 2301-7	1.9	84
117	Thrombotic thrombocytopenic purpura and hemolytic uremic syndrome. <i>Mayo Clinic Proceedings</i> , 2001 , 76, 1154-62	6.4	79
116	ASXL1 mutations are frequent and prognostically detrimental in CSF3R-mutated chronic neutrophilic leukemia. <i>American Journal of Hematology</i> , 2015 , 90, 653-6	7.1	58
115	Early peripheral blood blast clearance during induction chemotherapy for acute myeloid leukemia predicts superior relapse-free survival. <i>Blood</i> , 2007 , 110, 4172-4	2.2	57
114	Durable responses to thalidomide-based drug therapy for myelofibrosis with myeloid metaplasia. <i>Mayo Clinic Proceedings</i> , 2004 , 79, 883-9	6.4	57
113	Serious myeloproliferative reactions associated with the use of thalidomide in myelofibrosis with myeloid metaplasia. <i>Blood</i> , 2000 , 96, 4007-4007	2.2	57
112	Multidisciplinary model to implement pharmacogenomics at the point of care. <i>Genetics in Medicine</i> , 2017 , 19, 421-429	8.1	54
111	Pharmacokinetic Pharmacogenetic Prescribing Guidelines for Antidepressants: A Template for Psychiatric Precision Medicine. <i>Mayo Clinic Proceedings</i> , 2016 , 91, 897-907	6.4	51
110	3023 Mayo Clinic Patients With Myeloproliferative Neoplasms: Risk-Stratified Comparison of Survival and Outcomes Data Among Disease Subgroups. <i>Mayo Clinic Proceedings</i> , 2019 , 94, 599-610	6.4	50
109	Thrombocythaemia and pregnancy. <i>Best Practice and Research in Clinical Haematology</i> , 2003 , 16, 227-42	4.2	48
108	Thromboembolism in adults with acute lymphoblastic leukemia during induction with L-asparaginase-containing multi-agent regimens: incidence, risk factors, and possible role of antithrombin. <i>Leukemia and Lymphoma</i> , 2004 , 45, 1545-9	1.9	43
107	Cancer-associated microangiopathic hemolytic anemia with thrombocytopenia: an important diagnostic consideration. <i>European Journal of Haematology</i> , 2010 , 85, 43-50	3.8	36
106	Chronic neutrophilic leukemia and chronic myelomonocytic leukemia: WHO defined. <i>Best Practice and Research in Clinical Haematology</i> , 2006 , 19, 571-93	4.2	36

105	Venetoclax and hypomethylating agents in acute myeloid leukemia: Mayo Clinic series on 86 patients. <i>American Journal of Hematology</i> , 2020 , 95, 1511-1521	7.1	28
104	CALR mutation studies in chronic neutrophilic leukemia. <i>American Journal of Hematology</i> , 2014 , 89, 450	7.1	26
103	Chronic neutrophilic leukemia: a contemporary review. <i>Psychophysiology</i> , 2004 , 3, 210-7		24
102	Monocytosis is a powerful and independent predictor of inferior survival in primary myelofibrosis. <i>British Journal of Haematology</i> , 2018 , 183, 835-838	4.5	23
101	Therapy-related acute promyelocytic leukemia: observations relating to APL pathogenesis and therapy. <i>European Journal of Haematology</i> , 2012 , 88, 237-43	3.8	22
100	Chronic neutrophilic leukemia: 2018 update on diagnosis, molecular genetics and management. <i>American Journal of Hematology</i> , 2018 , 93, 578-587	7.1	19
99	Allogeneic hematopoietic stem cell transplant in adult patients with myelodysplastic syndrome/myeloproliferative neoplasm (MDS/MPN) overlap syndromes. <i>Leukemia and Lymphoma</i> , 2017 , 58, 872-881	1.9	18
98	CSF3R-mutated chronic neutrophilic leukemia: long-term outcome in 19 consecutive patients and risk model for survival. <i>Blood Cancer Journal</i> , 2018 , 8, 21	7	17
97	Venetoclax with azacitidine or decitabine in blast-phase myeloproliferative neoplasm: A multicenter series of 32 consecutive cases. <i>American Journal of Hematology</i> , 2021 , 96, 781-789	7.1	17
96	Chronic neutrophilic leukemia 2016: Update on diagnosis, molecular genetics, prognosis, and management. <i>American Journal of Hematology</i> , 2016 , 91, 341-9	7.1	17
95	Chronic neutrophilic leukemia 2014: Update on diagnosis, molecular genetics, and management. <i>American Journal of Hematology</i> , 2014 , 89, 651-8	7.1	16
94	Chronic neutrophilic leukemia: novel mutations and their impact on clinical practice. <i>Current Opinion in Hematology</i> , 2015 , 22, 171-6	3.3	15
93	Patients With Therapy-Related CMML Have Shorter Median Overall Survival Than Those With De Novo CMML: Mayo Clinic Long-Term Follow-Up Experience. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2015 , 15, 546-9	2	15
92	Pathogenesis and management of bleeding in essential thrombocythemia and polycythemia vera. <i>Psychophysiology</i> , 2004 , 3, 344-51		15
91	Mayo Alliance Prognostic Model for Myelodysplastic Syndromes: Integration of Genetic and Clinical Information. <i>Mayo Clinic Proceedings</i> , 2018 , 93, 1363-1374	6.4	14
90	Outcomes of plasma exchange in patients with transplant-associated thrombotic microangiopathy based on time of presentation since transplant. <i>Journal of Clinical Apheresis</i> , 2015 , 30, 147-53	3.2	13
89	Prognostic interaction between bone marrow morphology and SF3B1 and ASXL1 mutations in myelodysplastic syndromes with ring sideroblasts. <i>Blood Cancer Journal</i> , 2018 , 8, 18	7	13
88	Venetoclax plus hypomethylating agent in blast-phase myeloproliferative neoplasm: preliminary experience with 12 patients. <i>British Journal of Haematology</i> , 2020 , 191, e120-e124	4.5	13

87	Outcome of elderly patients after failure to hypomethylating agents given as frontline therapy for acute myeloid leukemia: Single institution experience. <i>American Journal of Hematology</i> , 2017 , 92, 866-874	7.1	12
86	The prognostic significance of trisomy 8 in patients with acute myeloid leukemia. <i>Leukemia and Lymphoma</i> , 2002 , 43, 583-6	1.9	12
85	Chronic neutrophilic leukemia: 2020 update on diagnosis, molecular genetics, prognosis, and management. <i>American Journal of Hematology</i> , 2020 , 95, 212-224	7.1	12
84	Prognostic impact of ASXL1 mutations in patients with myelodysplastic syndromes and multilineage dysplasia with or without ring sideroblasts. <i>Leukemia Research</i> , 2018 , 71, 60-62	2.7	11
83	Schistocytes on the Peripheral Blood Smear. <i>Mayo Clinic Proceedings</i> , 2004 , 79, 809	6.4	11
82	Safety and feasibility of lower antithrombin replacement targets in adult patients with hematological malignancies receiving asparaginase therapy. <i>Leukemia and Lymphoma</i> , 2017 , 58, 2588-2597	1.9	10
81	Primary Myelodysplastic Syndromes: The Mayo Clinic Experience With 1000 Patients. <i>Mayo Clinic Proceedings</i> , 2015 , 90, 1623-38	6.4	10
80	Hypomethylating agents (HMAs) effect on myelodysplastic/myeloproliferative neoplasm unclassifiable (MDS/MPN-U): single institution experience. <i>Leukemia and Lymphoma</i> , 2018 , 59, 2737-2739	1.9	8
79	Outcome of Myelodysplastic Syndromes Over Time in the United States: A National Cancer Data Base Study From 2004-2013. <i>Mayo Clinic Proceedings</i> , 2019 , 94, 1467-1474	6.4	8
78	Allogeneic hematopoietic cell transplantation improves outcome of adults with t(6;9) acute myeloid leukemia: results from an international collaborative study. <i>Haematologica</i> , 2020 , 105, 161-169	6.6	8
77	Prognostic impact of combined NPM1+/FLT3- genotype in patients with acute myeloid leukemia with intermediate risk cytogenetics stratified by age and treatment modalities. <i>Leukemia Research</i> , 2015 , 39, 1207-1207	2.7	7
76	A population-based study of chronic neutrophilic leukemia in the United States. <i>Blood Cancer Journal</i> , 2020 , 10, 68	7	7
75	The molecular genetics of chronic neutrophilic leukaemia: defining a new era in diagnosis and therapy. <i>Current Opinion in Hematology</i> , 2014 , 21, 148-54	3.3	7
74	Clinical outcomes of adults with hemophagocytic lymphohistiocytosis treated with the HLH-04 protocol: a retrospective analysis. <i>Leukemia and Lymphoma</i> , 2020 , 61, 1592-1600	1.9	6
73	Monosomal karyotype predicts adverse prognosis in patients diagnosed with chronic myelomonocytic leukemia: a single-institution experience. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2015 , 15, e39-41	2	6
72	Elderly acute lymphoblastic leukemia: a Mayo Clinic study of 124 patients. <i>Leukemia and Lymphoma</i> , 2019 , 60, 990-999	1.9	5
71	Response to erythropoiesis-stimulating agents in patients with WHO-defined myelodysplastic syndrome/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis (MDS/MPN-RS-T). <i>British Journal of Haematology</i> , 2020 , 189, e104-e108	4.5	4
70	Deficiency of Current Acute Myeloid Leukemia (AML) Response Criteria to Predict Response to Hypomethylating Agent Therapy: The Value of Long-Lasting Stable Disease. <i>Blood</i> , 2016 , 128, 2799-2799	2.2	4

69	Myeloid Sarcoma: The Mayo Clinic Experience of Ninety Six Case Series. <i>Blood</i> , 2016 , 128, 2798-2798	2.2	3
68	Outcome of Myelodysplastic Syndromes over Time in the US: A National Cancer Data Base Study from 2004-2013. <i>Blood</i> , 2016 , 128, 3604-3604	2.2	3
67	Cladribine therapy for advanced and indolent systemic mastocytosis: Mayo Clinic experience in 42 consecutive cases. <i>British Journal of Haematology</i> , 2021 ,	4.5	3
66	Acute myeloid leukemia after age 70 years: A retrospective comparison of survival following treatment with intensive versus HMA + venetoclax chemotherapy. <i>American Journal of Hematology</i> , 2021 , 96, E108-E111	7.1	3
65	The prognostic impact of bone marrow fibrosis in primary myelofibrosis. <i>American Journal of Hematology</i> , 2016 , 91, E454	7.1	3
64	Decreased survival and increased rate of fibrotic progression in essential thrombocythemia chronicled after the FDA approval date of anagrelide. <i>American Journal of Hematology</i> , 2019 , 94, 5-9	7.1	3
63	Clinical outcome of patients diagnosed with myelodysplastic syndrome-unclassifiable (MDS-U): single center experience. <i>Leukemia and Lymphoma</i> , 2019 , 60, 2483-2487	1.9	2
62	The Increasing Relevance of Copper Deficiency in Hematological Practice.. <i>Blood</i> , 2005 , 106, 1679-1679	2.2	2
61	Monocytosis Is a Powerful and Independent Predictor of Shortened Overall and Leukemia-Free Survival in Primary Myelofibrosis. <i>Blood</i> , 2016 , 128, 4249-4249	2.2	2
60	Early Peripheral Blood Blast Clearance during Induction Chemotherapy for Acute Myeloid Leukemia (AML) Predicts Superior Relapse-Free Survival.. <i>Blood</i> , 2007 , 110, 1848-1848	2.2	2
59	Clinical utility of fluorescence in situ hybridization-based diagnosis of BCR-ABL1 like (Philadelphia chromosome like) B-acute lymphoblastic leukemia. <i>American Journal of Hematology</i> , 2020 , 95, E68-E72	7.1	2
58	Frequency of venous thrombotic events in patients with myelodysplastic syndrome and 5q deletion syndrome during lenalidomide therapy. <i>Annals of Hematology</i> , 2019 , 98, 331-337	3	2
57	Multiple isodicentric Y chromosomes in myeloid malignancies: a unique cytogenetic entity and potential therapeutic target. <i>Leukemia and Lymphoma</i> , 2019 , 60, 821-824	1.9	2
56	The Impact of Obesity on the Outcomes of Adult Patients with Acute Lymphoblastic Leukemia - A Single Center Retrospective Study. <i>Blood and Lymphatic Cancer: Targets and Therapy</i> , 2021 , 11, 1-9	2.6	2
55	A novel predictive model of outcome in acute myeloid leukemia without favorable karyotype based on treatment strategy, karyotype and FLT3-ITD mutational status. <i>American Journal of Hematology</i> , 2018 , 93, E401-E404	7.1	2
54	Current treatment preferences in chronic myeloid leukemia: The Mayo Clinic Physicians' survey. <i>American Journal of Hematology</i> , 2017 , 92, E626-E627	7.1	1
53	Schistocytes on the Peripheral Blood Smear. <i>Mayo Clinic Proceedings</i> , 2004 , 79, 809	6.4	1
52	Efficacy of Venetoclax Plus Hypomethylating Agent in Blast Phase Myeloproliferative Neoplasm. <i>Blood</i> , 2020 , 136, 21-21	2.2	1

51	Chronic neutrophilic leukemia: 2022 update on diagnosis, genomic landscape, prognosis, and management.. <i>American Journal of Hematology</i> , 2022 ,	7.1	1
50	3,023 Mayo Clinic Patients with Myeloproliferative Neoplasms: Risk-Stratified Comparison of Survival and Outcomes Data Among Disease Subgroups. <i>Blood</i> , 2018 , 132, 3035-3035	2.2	1
49	Characteristics and Outcome of Patients with Core Binding Factor Acute Myeloid Leukemia and FLT3-ITD: Results from an International Collaboration. <i>Blood</i> , 2019 , 134, 2693-2693	2.2	1
48	Time Interval from Last Chemotherapy to Stem Cell Collection Correlates with Peripheral Blood Absolute Lymphocyte Count at Apheresis and Survival Post-Autologous Stem Cell Transplantation in Non-Hodgkin Lymphoma.. <i>Blood</i> , 2004 , 104, 2927-2927	2.2	1
47	Increasing the Number of Apheresis Collections Increases Lymphocyte Collection and Affects Survival after Autologous Stem Cell Transplantation for Non-Hodgkin Lymphoma.. <i>Blood</i> , 2004 , 104, 892-892	2.2	1
46	Cost-Effectiveness Of Antithrombin Repletion In Adult Patients With Acute Lymphoblastic Leukemia (ALL) Treated With Asparaginase-Containing Combination Chemotherapy; A Single Center Experience. <i>Blood</i> , 2013 , 122, 1732-1732	2.2	1
45	The Clinical Utility of Pharmacogenomics Testing in Assessing Tyrosine Kinase Inhibitor Therapy, Intolerance and Responses in Patients with Chronic Myelogenous Leukemia. <i>Blood</i> , 2018 , 132, 5440-5440	2.2	1
44	Response to Erythropoiesis Stimulating Agents in Patients with WHO-Defined Myelodysplastic Syndrome/Myeloproliferative Neoplasm with Ring Sideroblasts and Thrombocytosis (MDS/MPN-RS-T). <i>Blood</i> , 2019 , 134, 4182-4182	2.2	1
43	Thromboembolic and Hemorrhagic Complications In Adult Patients With Acute Lymphoblastic Leukemia (ALL) Treated With Asparaginase-Containing Combination Chemotherapy: A Single Center Experience. <i>Blood</i> , 2013 , 122, 3873-3873	2.2	1
42	Mayo Clinic experience with 1123 adults with acute myeloid leukemia. <i>Blood Cancer Journal</i> , 2021 , 11, 46	7	1
41	CSF3R T618I mutant chronic myelomonocytic leukemia (CMML) defines a proliferative CMML subtype enriched in ASXL1 mutations with adverse outcomes. <i>Blood Cancer Journal</i> , 2021 , 11, 54	7	1
40	Characteristics and outcome of patients with core binding factor acute myeloid leukemia and -ITD: results from an international collaborative study. <i>Haematologica</i> , 2021 ,	6.6	1
39	De novo isolated myeloid sarcoma: comparative analysis of survival in 19 consecutive cases. <i>British Journal of Haematology</i> , 2021 , 195, 413-416	4.5	1
38	Pancytopenia with focal serous atrophy (gelatinous transformation) of the bone marrow. <i>Journal of Hematopathology</i> , 2014 , 7, 91-92	0.4	0
37	Midostaurin therapy for indolent and smoldering systemic mastocytosis: retrospective review of Mayo Clinic experience.. <i>American Journal of Hematology</i> , 2022 ,	7.1	0
36	Cladribine Therapy for Advanced and Indolent Systemic Mastocytosis: Mayo Clinic Experience in 42 Consecutive Cases. <i>Blood</i> , 2021 , 138, 3657-3657	2.2	0
35	Pre-anthracycline echocardiogram rarely changes treatment strategy in acute myeloid leukemia. <i>American Journal of Hematology</i> , 2018 , 93, E144-E146	7.1	
34	Prior hypomethylating agent use lacks impact on clinical outcome in patients with secondary acute myeloid leukemia arising from myelodysplastic syndromes treated with standard induction chemotherapy. <i>International Journal of Hematology</i> , 2016 , 103, 409-15	2.3	

33	A Population-Based Study of Chronic Myelomonocytic Leukemia in the United States from 2004-2015. <i>Blood</i> , 2020 , 136, 30-31	2.2
32	Therapy-Related Cytopenia of Undetermined Significance (t-CCUS) As a Precursor to Therapy-Related Myeloid Neoplasms (t-MN). <i>Blood</i> , 2021 , 138, 1096-1096	2.2
31	Allogeneic Stem Cell Transplantation (SCT) in Untreated First Relapse or Following Re-Induction Chemotherapy for Patients with Acute Myeloid Leukemia (AML).. <i>Blood</i> , 2004 , 104, 5143-5143	2.2
30	Neutrophil and Eosinophil PRV-1 Expression in Atypical Myeloproliferative Disorders.. <i>Blood</i> , 2004 , 104, 1521-1521	2.2
29	Long Term Follow up of Allogeneic Hematopoietic Stem Cell Transplantation (ASCT) in Chronic Lymphocytic Leukemia (CLL).. <i>Blood</i> , 2005 , 106, 5420-5420	2.2
28	Low Incidence of FIP1L1-PDGFR α in Eosinophilic Patients and Long-Term Experience with Imatinib Therapy.. <i>Blood</i> , 2005 , 106, 2590-2590	2.2
27	Role of Second Stem Cell Transplant in Patients with Amyloidosis Who Are Refractory or Relapsing.. <i>Blood</i> , 2005 , 106, 5469-5469	2.2
26	Allogeneic Stem Cell Transplantation (ASCT) and Donor Lymphocyte Infusions (DLI) in the Management of Chronic Myelomonocytic Leukemia (CMML).. <i>Blood</i> , 2005 , 106, 5422-5422	2.2
25	Clinical Outcome of IgM Amyloidosis (AL) Following Stem Cell Transplantation.. <i>Blood</i> , 2005 , 106, 5470-5470	2.2
24	Frequency of Heparin-Induced Thrombocytopenia and Heparin-Dependent IgG Antibodies in Hematopoietic Stem Cell Transplant Recipients.. <i>Blood</i> , 2006 , 108, 4059-4059	2.2
23	Monocytosis Is an Independent Risk Factor for Survival in Agnogenic Myeloid Metaplasia.. <i>Blood</i> , 2006 , 108, 3629-3629	2.2
22	Engraftment Syndrome Is Common in Patients with POEMS Syndrome Undergoing PBSCT.. <i>Blood</i> , 2007 , 110, 2995-2995	2.2
21	Decreased Survival and Increased Rate of Fibrotic Progression in Essential Thrombocythemia Chronified after the FDA Approval Date of Anagrelide. <i>Blood</i> , 2018 , 132, 4287-4287	2.2
20	Indoleamine 2,3-Dioxygenase-1 Expressing Dendritic Cell Populations Are Associated with Tumor-Induced Immune Tolerance & Aggressive Disease Biology in Chronic Myelomonocytic Leukemia. <i>Blood</i> , 2018 , 132, 4344-4344	2.2
19	1,123 Consecutive Adults with Non-APL Acute Myeloid Leukemia: The Mayo Clinic Experience. <i>Blood</i> , 2018 , 132, 2689-2689	2.2
18	Discrepancy of Blast Percentage between the Bone Marrow Aspirate and Flow Cytometry and Its Impact on Survival Outcomes in Patients with Myelodysplastic Syndromes Excess Blast (MDS-EB). <i>Blood</i> , 2019 , 134, 5441-5441	2.2
17	Acute Myeloid Leukemia with High Risk Features: Routine Central Nervous System Evaluation May be Beneficial. <i>Blood</i> , 2019 , 134, 3863-3863	2.2
16	Survival Outcomes Following Allogeneic Stem Cell Transplantation for Inherited Bone Marrow Failure and Myeloid Germline Predisposition Syndromes. <i>Blood</i> , 2019 , 134, 3300-3300	2.2

- 15 Clinical Categorization of Chronic Myelomonocytic Leukemia into Proliferative and Dysplastic Subtypes Correlates with Distinct Genomic, Transcriptomic and Epigenomic Signatures. *Blood*, **2019**, 134, 1710-1710 2.2
- 14 Response to Hypomethylating Agents in Myelodysplastic Syndromes Based on WHO 2008 Subtypes and IPSS-R Stratification and Impact on Survival. *Blood*, **2015**, 126, 5260-5260 2.2
- 13 Clinical Characteristics and Outcome of Adult Acute Erythroleukemia; Mayo Clinic Experience. *Blood*, **2015**, 126, 4980-4980 2.2
- 12 Survival Trends in Adult T-Acute Lymphoblastic Leukemia / Lymphoma (ALL), a Comparative Analysis of 92 Patients By Year of Diagnosis. *Blood*, **2015**, 126, 2490-2490 2.2
- 11 Clofarabine Based Chemotherapy in Adult Relapsed/Refractory Acute Lymphoblastic Leukemia/Lymphoma-a Single Institution Experience. *Blood*, **2015**, 126, 4910-4910 2.2
- 10 Clinical Outcome of Therapy-Related Acute Myeloid Leukemia Is Strongly Related to Cytogenetic Analysis. *Blood*, **2015**, 126, 1401-1401 2.2
- 9 Disparity in the Overall Survival Improvement over Time and the Effect Time-to-Treatment on the Outcome of Acute Promyelocytic Leukemia: A US National Cancer Data Base Study from 1998-2011. *Blood*, **2015**, 126, 3747-3747 2.2
- 8 The Adverse Impact of Age and Central Nervous System Involvement on Survival in Adult T-ALL, an Analysis of 92 Consecutive Patients. *Blood*, **2015**, 126, 4993-4993 2.2
- 7 Outcome of Patients Younger Than 50 Years Old Diagnosed with Myelodysplastic Syndromes (MDS): Single Institution Experience. *Blood*, **2016**, 128, 5541-5541 2.2
- 6 Spectrum of Concomitant and Subsequently Diagnosed Second Malignancies in Patients with Chronic Myelomonocytic Leukemia. *Blood*, **2016**, 128, 1989-1989 2.2
- 5 Treatment-Related AML Patients Previously Treated with Taxanes for Breast Cancer Have Similar Outcomes As De Novo AML. *Blood*, **2012**, 120, 3555-3555 2.2
- 4 Cytogenetic Abnormalities Predict Clinical Outcome In Patients Diagnosed With Relapsed Acute Myeloid Leukemia (rAML): Single Center Experience. *Blood*, **2013**, 122, 4955-4955 2.2
- 3 Correlation Of Outcomes Of Allogeneic Stem Cell Transplants For Chronic Myelomonocytic Leukemia With The Mayo Prognostic Model. *Blood*, **2013**, 122, 5226-5226 2.2
- 2 Monosomal Karyotype Predicts Adverse Prognosis In Patients With Chronic Myelomonocytic Leukemia. *Blood*, **2013**, 122, 1334-1334 2.2
- 1 Management Of PICC-Associated Thrombosis In Patients Receiving Chemotherapy For Hematologic Malignancies. *Blood*, **2013**, 122, 5000-5000 2.2